Nestlé Health Science announced today that it will make an investment of USD 145 million in Aimmune Therapeutics, based in Brisbane (California, USA). The collaboration will accelerate the development of innovative oral immunotherapy biologics for people with food allergies, including peanut allergy sufferers. Read the press release on Nestlé Health Science's website:www.nestlehealthscience.com/newsroom/press-releases/Nestle-Health-Science-invests-in-Aimmune-Therapeutics More stories on our Nestlé News Feed: www.nestle.com/media
| 
